Medpace Holdings, Inc. operates as a clinical contract research organization (CRO) worldwide. The company solely focuses on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical devi…
Analysis
Quality compounder
Medpace Holdings, Inc. earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.
On valuation, the picture is expensive. The owner-earnings multiple stands at 29.4×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 11% a year, against analyst forecasts of 14%. The price, in other words, assumes less than the experts do.
Growth is solid; the safety picture is sturdy. The company scores 18/20 on our value-creation score: strong value creator.
No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.
360° rank · history
1007550250
Jan 202379
54
2023202420252026
All-time high
90
Jun 2024
All-time low
54
Mar 2026
Average rank
73
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
62
32
38
67
Price/Earnings
5
42
30
37
Price/Book
18
17
3
33
Dividend Yield
1
1
1
1
Value (overall)
1
9
9
35
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.